These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35447311)

  • 1. Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure.
    Gavriilidis E; Antoniadou C; Chrysanthopoulou A; Ntinopoulou M; Smyrlis A; Fotiadou I; Zioga N; Kogias D; Natsi AM; Pelekoudas C; Satiridou E; Bakola SA; Papagoras C; Mitroulis I; Peichamperis P; Mikroulis D; Papadopoulos V; Skendros P; Ritis K
    Clin Immunol; 2022 May; 238():109016. PubMed ID: 35447311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
    Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
    PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity.
    Troyer BS; Kovacic Scherrer N; Garavaglia J
    J Pharm Pract; 2024 Jun; 37(3):632-636. PubMed ID: 36803310
    [No Abstract]   [Full Text] [Related]  

  • 4. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.
    Hasan MJ; Rabbani R; Anam AM; Huq SMR; Polash MMI; Nessa SST; Bachar SC
    BMC Infect Dis; 2021 May; 21(1):427. PubMed ID: 33962573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical benefit of Tocilizumab and other immunomodulating agents for treatment of COVID-19].
    Hornuss D; Giesen R; Biever P; Kern WV
    Dtsch Med Wochenschr; 2021 Nov; 146(23):1538-1542. PubMed ID: 34826840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
    Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
    Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirement.
    Goldstein A; Neuberger A; Darawsha YQ; Hussein K; Shafat T; Grupel D; Strahilevitz J; Israel S; Weil A; Ben-Ami R; Elbaz M; Najjar-Debbiny R; Bishara J; Shlomai A; Landes M
    Sci Rep; 2024 Jul; 14(1):16985. PubMed ID: 39044026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
    Pérez-Alba E; Nuzzolo-Shihadeh L; Aguirre-García GM; Espinosa-Mora J; Lecona-Garcia JD; Flores-Pérez RO; Mendoza-Garza M; Camacho-Ortiz A
    J Microbiol Immunol Infect; 2021 Oct; 54(5):787-793. PubMed ID: 34294593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.
    Conroy GM; Bauer SR; Pallotta AM; Duggal A; Wang L; Sacha GL
    Pharmacotherapy; 2024 Jan; 44(1):28-38. PubMed ID: 37593883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19.
    Alunno A; Najm A; Machado PM; Bertheussen H; Burmester GR; Carubbi F; De Marco G; Giacomelli R; Hermine O; Isaacs JD; Koné-Paut I; Magro-Checa C; McInnes IB; Meroni PL; Quartuccio L; Ramanan AV; Ramos-Casals M; Rodríguez Carrio J; Schulze-Koops H; Stamm TA; Tas SW; Terrier B; McGonagle DG; Mariette X
    Ann Rheum Dis; 2022 Jan; 81(1):34-40. PubMed ID: 34620584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
    Kojima Y; Nakakubo S; Takei N; Kamada K; Yamashita Y; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454352
    [No Abstract]   [Full Text] [Related]  

  • 15. Baricitinib and Pulse Steroids Combination Treatment in Hyperinflammatory COVID-19: A Rheumatological Approach in the Intensive Care Unit.
    Ferro F; La Rocca G; Elefante E; Italiano N; Moretti M; Talarico R; Pelati E; Valentini K; Baldini C; Mozzo R; De Simone L; Mosca M
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Tocilizumab in COVID-19 patients: a cohort study.
    Vu CA; DeRonde KJ; Vega AD; Maxam M; Holt G; Natori Y; Zamora JG; Salazar V; Boatwright R; Morris SR; de Lima Corvino D; Betances AF; Colucci L; Keegan J; Lopez A; Rezk AH; Rodriguez Y; Moraru GM; Doblecki S; De La Zerda DJ; Abbo LM
    BMC Infect Dis; 2020 Dec; 20(1):964. PubMed ID: 33353546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
    Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
    Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
    Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
    PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.
    Rosas J; Liaño FP; Cantó ML; Barea JMC; Beser AR; Rabasa JTA; Adsuar FM; Auli BV; López IF; Sainz AMG; Ramis PE; Pérez LR; Rebollo MLN; Lorido RH; Escolar LG;
    Reumatol Clin (Engl Ed); 2022 Mar; 18(3):150-156. PubMed ID: 35277213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.